Regional spread of blaNDM-1-containing Klebsiella pneumoniae Sequence Type 147 in post-acute care facilities - Lapp, Zena; Crawford, Ryan; Miles-Jay, Arianna; Pirani, Ali; Trick, William E.; Weinstein, Robert A.; Hayden, Mary K.; Snitkin, Evan S.; Lin, Michael Y. (medRxiv, 2021)
Background Carbapenem-resistant Enterobacterales (CRE) harboring blaKPC have been endemic in Chicago-area healthcare networks for more than a decade. During 2016-2019, a series of regional point prevalence surveys identified increasing prevalence of blaNDM-containing CRE in multiple long-term acute care hospitals (LTACHs) and ventilator-capable skilled nursing facilities (vSNFs). We performed a genomic epidemiology investigation of blaNDM-producing CRE to understand their regional emergence and spread.Methods We performed whole-genome sequencing on NDM+ CRE isolates from four point-prevalence surveys across 35 facilities (LTACHs, vSNFs, and acute care hospital medical intensive care units) in the Chicago area and investigated the genomic relatedness and transmission dynamics of these isolates over time.Results Genomic analyses revealed that the rise of NDM+ CRE was due to the clonal dissemination of an ST147 Klebsiella pneumoniae strain harboring blaNDM-1 on an IncF plasmid. Dated phylogenetic reconstructions indicated that ST147 was introduced into the region around 2013 and likely acquired NDM around 2015. Analyzing genomic data in the context of patient transfer networks supported initial increases in prevalence due to intra-facility transmission in certain vSNFs, with evidence of subsequent inter-facility spread to connected LTACHs and vSNFs via patient transfer.Conclusions We identified a regional outbreak of blaNDM-1 ST147 that began in and disseminated across Chicago area post-acute care facilities. Our findings highlight the importance of performing genomic surveillance at post-acute care facilities to identify emerging threats.Competing Interest StatementM.L. and M.H. have received research support in the form of contributed product from OpGen, LLC and from Sage Products (now part of Stryker Corporation). M.L. has also received an investigator-initiated grant from CareFusion Foundation (now part of BD). M.H. and R.W. have participated in clinical studies where participating healthcare facilities received contributed product from Sage Products Inc., Molnlycke, Clorox, or Medline. Neither M.H., R.W. nor their hospitals received product, funding, payments, or any other form of compensation.Funding StatementThis work was supported by Centers for Disease Control and Prevention Cooperative Agreement [grant number U54 CK000481] and SHEPheRD [Task Order No. 200-2011-42037], the National Science Foundation Graduate Research Fellowship Program [grant number DGE 1256260 to Z.L.], the National Institutes of Health via the Molecular Mechanisms of Microbial Pathogenesis Training Grant [T32AI007528, A.M-J.] and the National Institutes of Health [1R01AI148259-01 to E.S.S.]. OpGen, Inc. (Gaithersburg, MD) provided Acuitas® multi-drug resistant organism gene test and Acuitas Resistome test in kind, during 2016-2017. Any opinions, findings, conclusions, or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the Centers for Disease Control and Prevention, National Science Foundation, or the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Bacterial isolates and de-identified clinical metadata were collected under a prior surveillance project that underwent ethical review at the CDC and was determined to be a nonresearch activity (public health surveillance). The project was also evaluated independently at each participating healthcare facility and either deemed a public health assessment or human subjects research and approved by local review boards where applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequenced isolates will be deposited under BioProject PRJNA686897. Code for analysis and visualization, as well as supplementary data, can be found here: https://github.com/Snitkin-Lab-Umich/ndm-st147-chicago-ms. https://www.ncbi.nlm.nih.gov/bioproject/?term=prjna686897 https://github.com/Snitkin-Lab-Umich/ndm-st147-chicago-ms